title: Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes.
abstract: A synthetic peptide that contains a Semliki Forest virus (SFV) B cell epitope, located at amino acid positions 240 to 255 of the E2 protein, and an SFV T helper (Th) cell epitope, located at positions 137 to 151 of the E2 protein, evoked high titres of SFV-reactive antibodies in H-2d mice. Although the peptide-induced antibodies did not neutralize SFV in vitro, 70 to 100% of the peptide-immunized mice were protected against SFV, even when viral challenge was presented 4 months after immunization. The protection could be transferred by anti-peptide serum, indicating that antibodies were responsible for the protection. When the Th cell epitope of this protective peptide was replaced by an influenza virus Th cell epitope or by another SFV Th cell epitope, the resulting peptides induced lower non-neutralizing SFV-reactive antibody titres and protected a correspondingly lower percentage of mice (50% and 30%, respectively). A peptide with the same Th cell epitope as the best protective peptide but with a less effective SFV B cell epitope protected only 33% of the mice. These results indicate that protection against SFV by a synthetic peptide is primarily dependent on its ability to induce adequate amounts of antibodies with relevant specificity and sufficient affinity; the ability to induce a relevant (SFV-specific) T memory response played only a minor role in protection.
authors.affiliation: Eijkman-Winkler Laboratory of Medical Microbiology, Academic Hospital Utrecht, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Snijders
authors.forename: B J
authors.initials: BJ
authors.lastname: Benaissa-Trouw
authors.forename: H
authors.initials: H
authors.lastname: Snippe
authors.forename: C A
authors.initials: CA
authors.lastname: Kraaijeveld
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000917:Antibody Formation / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D003429:Cross Reactions; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology*; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014036:Togaviridae Infections / Q000517:prevention & control* / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000939:Epitopes; D010455:Peptides; D014614:Vaccines, Synthetic